 Provider News New YorkNovember 2024 Provider Newsletter Contents
NYBCBS-CDCRCM-070463-24 HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). The Department of Health & Human Services (HHS) requires health plans to report whether or not our in-network providers offer telehealth services. If you provide telehealth services, please tell us by submitting your information to us through Availity.com. Updating your telehealth status will not affect your participation with us. We will add a telehealth indicator to your online provider directory profile, allowing our members to know you offer telehealth services. If you have questions about submitting your information, please see the instructions below. If your organization is not currently registered with Availity, you will need to create an account. The person(s) designated as your administrator(s) should go to Availity.com and select Get Started in the upper right corner of the webpage. You may also navigate directly to Availity’s registration website by selecting here. Begin your application here. To update your application: - Log in to Availity Essentials.
- Select My Providers.
- Select Provider Data Management.
Please update your telehealth information at the service location. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-069888-24-CPN69222 Beginning with claims processing on or after December 1, 2024, we will update our outpatient facility claims editing process to deny claim lines when an add-on code is reported without a primary procedure code. An add-on code is a specific type designated by the HCPCS or CPT®. These codes describe additional procedures or services performed with a primary procedure. According to CPT guidelines, add-on codes must be reported with a primary procedure code. If you believe you have received a claim denial in error, please follow our claim dispute process. With your help, we can continually build towards a future of shared success. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-070180-24-CPN69226 General Availability StandardsMembers must be able to access their PCP 24 hours a day, 7 days a week. As the Member’s healthcare manager, the PCP is responsible for providing or arranging healthcare services on a 24/7 basis. (An answering machine does not suffice as access to the Provider.) The PCP must also have a method to inform his or her Anthem Members about regular office hours and how to obtain care after office hours. When off-duty or otherwise unavailable, the PCP must arrange for back-up coverage by a network physician so that appropriate medical care is available to Members at all times. The PCP must have available the name, telephone number and address of the physician(s) responsible for providing back-up services to patients. The PCP should contact Anthem Physician Services at 800-552-6630, 8:30 a.m. to 5:00 p.m. ET, Monday to Friday or Provider Data Management via fax at 518-367-3103 if the designated back-up changes. The designated back-up physician(s) must participate in the same network and be a comparably trained practitioner as noted below: - Family Practice – can be backed up by a Provider with the following specialties:
Family Practice; General Practice and/or a combination consisting of Internal Medicine – for adults and Pediatrics for Children. - General Practice – can be backed up by a Provider with the following specialties:
Family Practice; General Practice and/or a combination consisting of Internal Medicine –for adults and Pediatrics for Children. - Internal Medicine – can be backed up by a Provider with the following specialties:
Internal Medicine or Family Practice. Pediatrics – can be backed up by a Provider with the following specialties: Family Practice or Pediatrics
The back-up physician is responsible for communicating with the PCP about patient care he or she rendered. Documentation of all healthcare services provided by the back-up physician must be summarized in the patient’s medical record including all pertinent Facility services. If a Member is out of the area and contacts Anthem with an urgent or emergent situation, the patient will be informed to call his or her PCP directly. If this is not possible, the patient will be told to contact the PCP’s back-up physician. Annually, Anthem will conduct an audit of the after hour availability coverage for PCP network participation to ensure compliance. Compliance will be met if: - A live person is reached within two (2) phone calls.
- If an answering service is reached; compliance will be met if the service is cooperative in confirming their association with the physician and identifies how the physician can be reached (ex. pager; calls patched to physician)
In no event shall the messages refer the Member to the ER unless it is a true emergency or advise to call back during normal business hours. Appointment Availability StandardsThe following are considered minimums for patient accessibility. Obviously, excellent care and service will often require significantly better performance. For HMO and POS Members, the PCPs must be in the office treating patients a minimum of 16 hours a week per office location. Patients should not wait for more than 15 minutes past their appointment time without an explanation about the delay and if necessary, provided with an opportunity to reschedule the appointment. - The physician must be able to schedule appointments within the following time frames:
- Type of Appointment Time Frame
- Routine baseline physical exam Within 4 weeks
- Routine follow-up care Within 2 weeks
- Urgent Care Within 24 hours
- Non-Urgent Care Within 5 days
- Emergency Care Within 2 hours or triage to emergency room
- Initial prenatal exam Within 3 weeks
- Initial newborn exam Within 2 weeks
- Availability standards will be monitored through:
- On-site visits by Network Management Consultant,
- Review of appointment books,
- Member satisfaction surveys, and
- Member complaints
PHYSICIAN RESPONSIBILITIES All participating Providers are expected to comply with certain standards regardless of the networks in which they participate. These include: - Following Anthem’s access/appointment availability standards
- Following Anthem’s managed care requirements (if applicable to the Member’s benefit plan). Adhering to Anthem’s standard practice guidelines
- Submitting Claims for Members, accepting program/network fee schedule and not balance billing Members for covered services
- Not prohibiting Members from completing Anthem surveys and/or otherwise expressing their opinion regarding services received from physicians or Providers
- Will not differentiate or discriminate against any Member as a result of his/her enrollment in a Plan, or because of race, color, creed, national origin, ancestry, religion, sex, marital status, age, disability, payment source, state of health, need for health services, status as a litigant, status as a Medicare or Medicaid beneficiary, sexual orientation, or any other basis prohibited by law. Provider shall not be required to provide any type, or kind of Health Service to Covered Members that it does not customarily provide to others.
HMO PhysiciansPhysicians participating in the HMO-based networks have certain additional responsibilities, based upon their roles as primary care physicians and/or referral specialists. Primary Care PhysiciansA Primary Care Physician (PCP) is a family physician/family practitioner, general practitioner, internist or pediatrician who is responsible for delivering and/or coordinating care. PCPs must: - Be accessible 24 hours a day, 7 days a week, and provide back-up coverage
- Provide or arrange for all care delivered to HMO Members
- Provide written referrals to referral specialists, to the extent required by the Member’s benefit plan
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-068404-24, NYBCBS-CM-070716-24, PCTS-1060, NYBCBS-CM-074922-24 To ensure continuous 24-hour coverage, primary care physicians (PCP) must maintain one of the following arrangements for their members to contact the PCP after normal business hours: - Have the office telephones answered after-hours by an answering service, which can contact the PCP or another designated network medical practitioner.
- Have the office telephone answered after normal business hours by a recording in the language of each of the major population groups served by the PCP, directing the member to call another number to reach the PCP or another provider designated by the PCP. Someone must be available to answer the designated provider’s telephone; another recording is not acceptable.
- Have the office telephone transferred after office hours to another location where someone will answer the telephone and be able to contact the PCP or a designated Anthem network medical practitioner.
Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-066421-24, NYBCBS-CD-070717-24, NYBCBS-CD-079726-25 In July, we announced an enhancement to the 277CA to notify you of submission errors discovered during claims processing.
As of November 1, 2024, the 277CA will include additional corrective action types for your review. As communicated in July, these errors will still be sent through physical mailing.
With these added error types, there is no reduction to the services we already provide.
Through our efforts, we are committed to reducing administrative burden, improving communication, and ensuring timely payments because we value you, our care provider partners.
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-069544-24-CPN69313 Find Care, the doctor finder and transparency tool in the Anthem online directory, provides Anthem members with the ability to search for in-network providers using the secure member website. This tool currently offers multiple sorting options such as sorting providers based on distance, alphabetical order, and provider name. In our November 2022 newsletter, we provided an update regarding Personalized Match, an additional Find Care sorting option for Commercial members. We informed you that this provider sorting option was based on provider efficiency and quality outcomes described in a methodology document linked in the newsletter article, in addition to member search radius. We want to inform you that, beginning in December 2024 or later, we will be enhancing Personalized Match. This will expand upon the existing program. Newer components of the provider personalization metrics will contain up to 10 times as many features as compared to existing metrics such as gaps in care and additional types of service cost and utilization. Personalized Match will continue to display providers with the highest overall ranking within the member’s search radius, first. Members will continue to have the ability to sort based on distance, alphabetical order, and provider name. Helpful resources on AvailityYou may review a copy of the Personalized Match methodology that has been posted on Availity, our secure web-based provider tool, using the following navigation: - Go to Availity > Payer Spaces > Health Plan > Education & Reference Center > Administrative Support > Personalized Match Methodology.pdf.
If you have general questions regarding these upcoming changes, please submit an inquiry via the web at Availity.com. If you would like information about your quality or efficiency scoring used as part of this sorting option or if you would like to request reconsideration of those scores, you may do so by submitting an inquiry to Availity.com. Anthem will continue to focus and expand our consumer tools and content to assist members in making more informed and personalized healthcare decisions. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-061391-24, MULTI-BCBS-CM-070287-24 Summary: - The Personalized Match sorting option in the Find Care tool will be enhanced to provide more personalized care provider suggestions based on gaps in care and member history derived from clinical data, beginning December 2024.
- Members will be able to find details on the enhanced Personalized Match methodology in the online directory, and care providers will be able to submit inquiries or request reconsideration of care provider scores.
Find Care, the provider finder and transparency tool in the Anthem online directory, allows members to search for in-network care providers using the secure member website at anthem.com/find-care. This tool currently offers multiple sorting options, such as sorting providers based on Personalized Match, distance, alphabetic order, and care provider name. Beginning December 2024 or later, the Personalized Match sorting option will be enhanced for members. This sorting option currently considers care provider efficiency and quality outcomes. Enhancements will include gaps in care, such as HEDIS® measures and other market-specific clinical care measures, knowledge about member history derived from claims and other available clinical data, and member search radius. Care provider pairings with the highest overall ranking within the member’s search radius will be displayed first. Members will continue to be able to sort based on distance, alphabetic order, and care provider name: - You may review a copy of the Personalized Match methodology that has been posted on Availity Essentials — our secure web-based care provider tool — using the following navigation: Go to Availity.com > Payer Spaces > Select the Payer > Provider Online Reporting > Programs > Select a Program > Personalized Match > Personalized Match Methodology Phase 2 - Medicaid.pdf.
- If you have general questions regarding this new sorting option, please submit an inquiry to Availity.com.
- If you would like information about your quality or efficiency scoring used as part of this sorting option or if you would like to request reconsideration of those scores, you may do so by submitting an inquiry to Availity.com.
HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-065650-24-CPN65561 At a glance:- Professional care providers can now access and download fee schedules from Availity Essentials.
- Historical, current, and future rates are available in one centralized location.
- Administrators must assign specific user roles to access the fee schedule application.
You can now request your Professional Provider Fee Schedule via the Provider Enrollment and Network Management application through the Availity Essentials website: - All professional care providers can download the complete fee schedule within minutes.
- Care providers will be able to pull historic fee schedules (up to three years) in addition to current and future rate(s).
- This is one centralized location to access your Commercial network fee schedules.
See details below on how to log in and access your fee schedule application. If your organization is not currently registered for Availity Essentials, go to Availity.com and select Get Started to complete the online application. How to get started Your administrator will need to assign the user role of Provider Enrollment and Fee Schedule, from Manage My Team(s) on Availity.com to access the application. Accessing your fee schedule: - Log in to Availity.com.
- Select Payer Spaces in the top menu bar.
- Select the Anthem Blue Cross and Blue Shield payer title.
- Accept the User Agreement (once every 365 days).
- On the Applications tab, select Provider Enrollment and Network Management.
- Select the Request Fee Schedule link under the My Fee Schedule option on the side menu.
- Enter the information in the form, select the Commercial network you want to get the fee schedule for, and select Submit.
- On successful submission, select the Fee Schedule Result link to view the result file.
Important notes:- It might take up to 15 minutes for your rates file to be ready to download. Refresh the results page and the download icon will display.
- The downloaded file is in Excel format. Read through the disclaimer before using the rates.
- Review the Reference Guide for the fee schedule from our learning center by navigating to Payer Spaces > Custom Learning Center application > Courses section.
Contact usWe are committed to a future of shared success. Availity Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to Availity.com and select the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat. For additional support, visit the Contact Us section of our provider website for the appropriate contact. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-069788-24 We are excited to announce the release of an Applied Behavior Analysis (ABA) Provider Resource Guide designed to assist with proper billing and documentation practices. This essential guide simplifies the complexities of ABA coding and requirements, ensuring that you can navigate these processes with ease. Refer to attached ABA Provider Resource Guides. Commercial services provided by Anthem Blue Cross, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-072382-24-CPN72379, NYBC-CM-072381-24-CPN72379, MULTI-BCBS-CM-072378-24-CPN72366, NYBC-CM-072377-24-CPN72366 ATTACHMENTS (available on web): ABA Provider Resource Guide - Anthem Blue Cross (pdf - 0.37mb) ABA Provider Resource Guide - Anthem Blue Cross Blue Shield (pdf - 0.39mb) As respiratory syncytial virus (RSV) season approaches, we would like to remind providers about available RSV immunizations to help prevent severe RSV related disease in infants. According to a report from the CDC (March 2024), infant preventive antibodies showed 90% effectiveness against the need for hospitalization for RSV in babies. Two immunizations are available to prevent RSV lower respiratory tract infections in infants: - Pfizer's Abrysvo, a maternal vaccine given during pregnancy
- Nirsevimab (Beyfortus), a monoclonal antibody administered to the baby
The maternal vaccine, Abrysvo, is recommended for those who are 32 to 36 weeks pregnant during RSV season, which generally falls between October and March. The vaccine can provide protection for infants up to six months if the mother receives it at least two weeks prior to delivery. Nirsevimab (Beyfortus) provides up to five months of protection against RSV and is approved for infants under 8 months during their first RSV season, and certain children between 8 and 19 months at increased risk of severe RSV disease. In some cases where a mother received an RSV vaccine, Nirsevimab can still be considered for the child if there is a substantial risk for severe RSV disease or if the maternal immune response to the vaccination is inadequate. Nirsevimab is covered under the Vaccines for Children Program. Additional information about RSV prevention and Nirsevimab (Beyfortus) can be found at cdc.gov/rsv. We look forward to sharing resources and working with you to achieve improved outcomes for children in our communities. Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-068148-24-CPN67753 As a contracted provider for a special needs plan (SNP) from Anthem, you are required to participate in an annual Model of Care training for providers, per CMS regulations. This training includes a detailed overview of Anthem special needs plans and program information, highlighting cost sharing, data sharing, participation in the Interdisciplinary Care team (ICT), where to access the member’s health risk assessment results, plan of care, and benefit coordination. Please remember this training is specific to our plans and delivery of care for members, ensuring their specific care needs are met. Your participation is critical for improved quality and health outcomes. Training for the SNP product is self-paced and available at Availity.com. The training must be completed by December 31, 2024. How to access the Custom Learning Center:- Log in to the Availity website at Availity.com.
- At the top of the Availity website, select Payer Spaces and select the appropriate payer.
- On the Payer Spaces landing page, select Access Your Custom Learning Center from Applications.
- In the Custom Learning Center, select Required Training.
- Select Special Needs Plan and Model of Care Overview.
- Select Enroll.
- Select Start.
- Once the course is completed, select Begin Attestation and complete.
Not registered for Availity Essentials?Have your organization’s designated administrator register your organization for the Availity website: - Visit Availity.com to register.
- Select Register.
- Select your organization type.
- In the Registration wizard, follow the prompts to complete the registration for your organization.
Refer to these PDF documents for complete registration instructions. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-070560-24-CPN70218 In the July 2024 edition of Provider News, we announced the transition to the following Carelon Medical Benefits Management guidelines: Site of Care for Advanced Imaging, Rehabilitative Site of Care, and Surgical Site of Care, effective September 1, 2024. To clarify, existing prior authorization requirements have not changed, and this does not equate to the presence of a site of care review requirement. In the event a site of care review requirement for these services will be implemented, a separate notice will be distributed before the addition of any such requirements. You may access and download a copy of the current and upcoming guidelines here. Site of Care Guidelines: - Site of Care for Advanced Imaging
- Rehabilitative Site of Care
- Surgical Site of Care
Please share this notice with other members of your practice and office staff. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-067576-24-CPN67268 In the July 2024 edition of Provider News, we announced the transition to the following Carelon Medical Benefits Management guidelines: Site of Care for Advanced Imaging, Rehabilitative Site of Care, and Surgical Site of Care effective September 1, 2024. To clarify, existing prior authorization requirements have not changed, and this does not equate to the presence of a site of care review requirement. In the event a site of care review requirement for these services will be implemented, a separate notice will be distributed before the addition of any such requirements. You may access and download a copy of the current and upcoming guidelines here: - Site of Care Guidelines:
- Site of Care for Advanced Imaging
- Rehabilitative Site of Care
- Surgical Site of Care
Please share this notice with other members of your practice and office staff. Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-067597-24-CPN67275 Effective November 17, 2024 This article was updated on November 24, 2024 to change the effective date from October 26, 2024 to November 17, 2024. Effective on November 17, 2024, the following Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guideline updates will be adopted for Anthem. This article is to communicate the plan adoption of these Carelon Medical Benefits Management, Inc. guidelines. Existing prior authorization requirements have not changed. In the event a prior authorization requirement or site of care review requirement for these services will be implemented, a separate notice will be distributed before the addition of any such prior authorization or site of care review requirement. You may access and download a copy of the current and upcoming guidelines here: - Musculoskeletal:
- Site of Care:
- Site of Care for Advanced Imaging
- Rehabilitative Site of Care
- Surgical Site of Care
The above guideline updates have a publish date of November 17, 2024. Please share this notice with other members of your practice and office staff. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-065139-24-CPN64434, MULTI-ALL-CR-074348-24 Effective November 30, 2024 Effective on November 30, 2024, the following Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines updates will be adopted for Anthem. This article is to communicate the plan adoption of these Clinical Appropriateness Guidelines. Existing prior authorization requirements have not changed. In the event a prior authorization requirement or site of care review requirement for these services will be implemented, a separate notice will be distributed before the addition of any such prior authorization or site of care review requirement. You may access and download a copy of the current and upcoming guidelines here. - Musculoskeletal:
- Site of Care:
- Site of Care for Advanced Imaging
- Rehabilitative Site of Care
- Surgical Site of Care
The above guideline updates have a publish date of November 17, 2024. Please share this notice with other members of your practice and office staff. Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-067234-24-CPN66675 Effective November 3, 2024 The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised during Quarter Two, 2024. Note, several policies and guidelines were revised to provide clarification only and are not included. Some may have expanded rationales, medical necessity indications, or criteria, and some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary. Please share this notice with other providers in your practice and office staff. To view a guideline, visit Provider Medical Policies. Notes/updatesUpdates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive: - MED.00148 — Gene Therapy for Metachromatic Leukodystrophy:
- Outlines the Medically Necessary and Not Medically Necessary criteria for gene therapy for metachromatic leukodystrophy
- RAD.00069 — Absolute Quantitation of Myocardial Blood Flow Measurement:
- The use of absolute quantitation of myocardial blood flow testing is considered Investigational & Not Medically Necessary for all indications
- SURG.00011 — Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting:
- Revised ocular indications, including the addition of SurSight to Medically Necessary and Not Medically Necessary section and added new Medically Necessary criterion addressing non-healing or persistent corneal epithelial defects
- Removed VersaWrap from Investigational & Not Medically Necessary statement
- Removed Phasix Mesh from Investigational & Not Medically Necessary statement
- Added Phasix Mesh and Phasix ST Mesh to Medically Necessary and Not Medically Necessary statements
- CG-DME-54 — Mechanical Insufflation-Exsufflation Devices:
- Outlines the Medically Necessary and Not Medically Necessary criteria for use of mechanical insufflation-exsufflation devices
Medical PoliciesOn May 9, 2024, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Anthem. These medical policies take November 3, 2024. Publish Date | Medical Policy Number | Medical Policy Title | New or Revised | 6/28/2024 | ANC.00009 | Cosmetic and Reconstructive Services of the Trunk, Groin, and Extremities | Revised | 5/16/2024 | *MED.00148 | Gene Therapy for Metachromatic Leukodystrophy | Revised | 6/28/2024 | *RAD.00069 | Absolute Quantitation of Myocardial Blood Flow Measurement | New | 6/28/2024 | *SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Revised | 6/28/2024 | SURG.00121 | Transcatheter Heart Valve Procedures | Revised |
Clinical UM GuidelinesOn May 9, 2024, the MPTAC approved the following Clinical UM Guidelines applicable to Anthem. These guidelines were adopted by the medical operations committee for Medicaid members on June 27, 2024. These guidelines take effect November 3, 2024. Publish Date | Clinical UM Guideline Number | Clinical UM Guideline Title | New or Revised | 6/28/2024 | *CG-DME-54 | Mechanical Insufflation-Exsufflation Devices | New | 6/28/2024 | CG-DME-55 | Automated External Defibrillators for Home Use | New | 6/28/2024 | CG-MED-68 | Therapeutic Apheresis | Revised | 6/28/2024 | CG-MED-97 | Biofeedback and Neurofeedback | New |
Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-068657-24-CPN68109 The following services will be added to precertification for the effective dates listed below. Eligibility and benefits can be verified by accessing Availity at Availity.com or calling Anthem’s Utilization Management department using the number on the back of the member’s identification card. Service preapproval is based on member’s benefit plan/eligibility at the time the service is reviewed/approved. Precertification can help avoid unnecessary charges or penalties by helping to ensure that the member's care is medically necessary and administered at an appropriate network facility and by a network provider. Add to precertification | Criteria | Criteria description | Code | Effective date | MED.00140 | Gene Therapy for Beta Thalassemia | J3393 | 2/1/2025 | MED.00146 | Gene Therapy for Sickle Cell Disease | J3394 | 2/1/2025 |
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-068529-24 The following services will be added to precertification for the effective dates listed below. To obtain precertification, providers can access Availity @ www.availity.com or call Anthem’s Utilization Management department using the number on the back of the member’s identification card. Service preapproval is based on member’s benefit plan/eligibility at the time the service is reviewed/approved. Precertification can help avoid unnecessary charges or penalties by helping to ensure that the member's care is medically necessary and administered at an appropriate network facility and by a network provider. Add to Precertification | Criteria | Criteria Description | Code | Effective Date | LAB.00042 | Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy | 0456U | 2/1/2025 | LAB.00046 | Testing for Biochemical Markers for Alzheimer’s Disease | 0459U | 2/1/2025 | LAB.00019 | Proprietary Algorithms for Liver Fibrosis | 0468U | 2/1/2025 | TRANS.00039 | Portable Normothermic Organ Perfusion Systems | 0894T | 2/1/2025 | TRANS.00039 | Portable Normothermic Organ Perfusion Systems | 0895T | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J0687 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J0688 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J0689 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J0744 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J2183 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J2184 | 2/1/2025 | MED.00013 | Parenteral Antibiotics for the Treatment of Lyme Disease | J2281 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4311 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4312 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4313 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4314 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4315 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4316 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4317 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4318 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4319 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4320 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4321 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4322 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4323 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4324 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4325 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4326 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4327 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4328 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4329 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4330 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4331 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4332 | 2/1/2025 | SURG.00011 | Allogeneic, Xenographic, Synthetic, Bioengineered, and Composite Products for Wound Healing and Soft Tissue Grafting | Q4333 | 2/1/2025 |
UM AROW A2024M2180 Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-067491-24 Effective December 1, 2024 Effective December 1, 2024, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicaid members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these PA rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Description | 0141U | Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected | 0142U | Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected | 0321U | Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique | 0449T | Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device | 21086 | Impression & Custom Preparation; Auricular Prosthesis | 36468 | Injection(s) of sclerosant for spider veins (telangiectasia), limb or trunk | 36473 | Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated | 37241 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (for example, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles) | 61885 | Subq Placement Cranial Neurostimulator Pulse Generator/Receiver; W/Connection Sngle Electrod Array | 64568 | Open implantation of cranial nerve (for example, vagus nerve) neurostimulator electrode array and pulse generator | 64569 | Revision or replacement of cranial nerve (for example, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator | 66183 | Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach | 66989 | Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (for example, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (for example, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (for example, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more | 66991 | Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (for example, irrigation and aspiration or phacoemulsification); with insertion of intraocular (for example, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more | 82107 | Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio) | 86304 | Immunoassay, Tumor Antigen, Quantitative; Ca 125 | 95976 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (for example, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional | 95977 | Electronic analysis of implanted neurostimulator pulse generator/transmitter (for example, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional | 97760 | Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(ies), lower extremity(ies) and/or trunk, initial orthotic(s) encounter, each 15 minutes | 97763 | Orthotic(s)/prosthetic(s) management and/or training, upper extremity(ies), lower extremity(ies), and/or trunk, subsequent orthotic(s)/prosthetic(s) encounter, each 15 minutes | A2026 | Restrata MiniMatrix, 5 mg | A4438 | Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each | C1734 | Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable) | C9796 | Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (for example, porcine small intestine submucosa [SIS]) | C9797 | Vascular embolization or occlusion procedure with use of a pressure-generating catheter (for example, one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction | E0735 | Non-invasive vagus nerve stimulator | E2298 | Complex rehabilitative power wheelchair accessory, power seat elevation system, any type | Q4305 | American Amnion AC Tri-Layer, per sq cm | Q4306 | American Amnion AC, per sq cm | Q4307 | American Amnion, per sq cm | Q4308 | Sanopellis, per sq cm | Q4309 | VIA Matrix, per sq cm | Q4310 | Procenta, per 100 mg |
To request PA, you may use one of the following methods: - Web: Log in to Availity.com
- Fax: 800-964-3627
- Phone: 800-450-8753
Not all PA requirements are listed here. Detailed PA requirements are available to providers on https://providers.anthem.com/ny on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call Provider Services at 800-450-8753 for assistance with PA requirements. UM AROW #: A2024M187 Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-065602-24-CPN65118 Effective February 1, 2025 Effective February 1, 2025, prior authorization (PA) requirements will change for the following code(s). The medical code(s) listed below will require PA by Anthem for Medicare Advantage members. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non‑compliance with new requirements may result in denied claims. Prior authorization requirements will be added for the following code(s): Code | Code description | 0456U | Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti-cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy PrismRA®, Scipher Medicine®, Scipher Medicine® | 0459U | β-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology Elecsys® Total Tau CSF (tTau) and β-Amyloid (1-42) CSF II (Abeta 42) Ratio, Roche Diagnostics Operations, Inc (US owner/operator) | 0468U | Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis NASHnext™ (NIS4™), Labcorp, Labcorp | J0687 | Injection, cefazolin sodium (WG Critical Care), not therapeutically equivalent to J0690, 500 mg | J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | J2183 | Injection, meropenem (WG Critical Care), not therapeutically equivalent to J2185, 100 mg | J2184 | Injection, meropenem (B. Braun), not therapeutically equivalent to J2185, 100 mg | J2281 | Injection, moxifloxacin (Fresenius Kabi), not therapeutically equivalent to J2280, 100 mg |
Not all PA requirements are listed here. Detailed PA requirements are available to providers on anthem.com/medicareprovider on the Resources tab or for contracted providers by accessing Availity.com. Providers may also call Provider Services at the number on the back of the patient’s member ID card for assistance with PA requirements. UM AROW #: A2024M2186 Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-068215-24-CPN67511 Beginning with dates of service on or after February 1, 2025, Anthem will update the Nurse Practitioner and Physician Assistant Services — Professional reimbursement policy as indicated below. The following services will be removed from the policy and are eligible for a payment reduction when billed by a nurse practitioner (NP) or physician assistant (PA) provider: - Preventive Services
- Radiology Services
The following services will be added to the policy and will not be considered for a payment reduction when billed by a nurse practitioner (NP) or physician assistant (PA) provider: - Drugs
- Durable Medical Equipment, Prosthetics, Orthotics and Supplies
- Laboratory Services and Laboratory Screening Tests
For specific policy details, visit the reimbursement policy page by selecting here. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-069779-24 At a glance: - High Performing Providers will also be known as Anthem Diamond Providers.
- Providers receiving a designation based on the Blue National Physician Performance Dataset will also be known as Anthem Diamond Providers (National).
High Performing Provider programOver the last several months, we have communicated with our providers about our High Performing Provider program. PCPs and specialists meeting certain criteria are designated High Performing Providers. High Performing Providers may also be referred to as Anthem Diamond Providers. As a reminder, the following specialties may be designated High Performing Providers (aka Anthem Diamond Providers) from this program: - PCP: family practice, general practice, geriatric medicine, internal medicine, pediatric medicine, and nurse practitioners
- Specialists: cardiology, endocrinology, nephrology, neurology, neurosurgery, obstetrics gynecology, orthopedic surgery, psychiatry, pulmonology, and rheumatology
If you have any questions about this program, contact Provider Services or your local provider relationship management representative. Blue National Physician Performance DatasetThis is an Anthem designation program for providers in networks supporting Anthem national accounts and certain out-of-area providers. As we previously communicated to you, effective January 1, 2025, Anthem may incorporate insights from the Blue National Physician Performance Dataset (Dataset) in various initiatives. For Anthem national accounts and certain out-of-area providers, Anthem will use data made available in the Dataset to assess individual physician’s performance at the NPI level. The individual physician’s performance is assessed across the three domains — cost of care/efficiency, quality of care, and appropriateness of care — for the following 16 primary care and specialty areas: cardiothoracic surgery, cardiovascular disease, endocrinology, neurology, ob/gyn, ophthalmology, orthopedics, pediatrics, primary care, pulmonology, surgery, urology, gastroenterology, otolaryngology, oncology, and radiation oncology. The providers who qualify for the designation from this Dataset program will also be referred to as Anthem Diamond Providers (National). If you have any questions regarding this, contact your local provider relationship management representative. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-070326-24 This article was updated on October 9, 2024, to remove Ilumya as non-preferred from the step therapy requirements section below. Ilumya is not being added to the step therapy program at this time. Specialty pharmacy updates for Anthem are listed below. Anthem’s medical specialty drug review team manages prior authorization (PA) clinical review of non-oncology use of specialty pharmacy drugs. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company. Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request PA review for your patients’ continued use of these medications. Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code. Prior authorization updates Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our PA review process. Access our Clinical Criteria to view the complete information for these prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® Code(s) | CC-0003* | Alyglo (immune globulin intravenous, human-stwk) | J1599 | CC-0062 | Simlandi (adalimumab-ryvk) | J3590 | CC-0261 | Winrevair (sotatercept-csrk) | C9399, J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Note: PA requests for certain medications may require additional documentation to determine medical necessity. Step therapy updates Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our existing specialty pharmacy medical step therapy review process. Access our Clinical Criteria to view the complete information for these step therapy updates. Clinical Criteria | Status | Drug | HCPCS or CPT Code(s) | CC-0003 | Non-preferred | Alyglo (immune globulin intravenous, human-stwk) | J1599 | CC-0062 | Non-preferred | Cimzia (certolizumab pegol) | J0717 | CC-0042 | Non-preferred | Cosentyx intravenous (secukinumab) | C9399, J3490, J3590, C9166 | CC-0050 | Non-preferred | Omvoh (mirkizumab-mrkz) | C9168, J3590 |
Quantity limit updates Effective for dates of service on or after October 1, 2024, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT Code(s) | CC-0062 | Simlandi (adalimumab-ryvk) | J3590 | CC-0261 | Winrevair (sotatercept-csrk) | C9399, J3590 |
Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-060687-24-CPN60563, MULTI-BCBS-CM-069897-24 Specialty pharmacy updates for Anthem are listed below. Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc., a separate company. Note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications. Inclusion of the national drug code (NDC) on your claim will help expedite claim processing of drugs billed with a not otherwise classified (NOC) code. Prior authorization updatesEffective for dates of service on or after February 1, 2025, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. Access our Clinical Criteria to view the complete information for these prior authorization updates. Clinical Criteria | Drug | HCPCS or CPT® code(s) | CC-0027* | Jubbonti; Wyost (denosumab-bbdz) | Q5136 | CC-0002* | Nypozi (filgrastim-txid) | C9399, J3590 | CC-0266* | Rytelo (imetelstat) | C9399, J9999 | CC-0003* | Yimmugo (immune globulin intravenous, human–dira) | J3590 |
* Oncology use is managed by Carelon Medical Benefits Management. Step therapy updatesEffective for dates of service on or after February 1, 2025, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our existing specialty pharmacy medical step therapy review process. The current Orencia step therapy preferred product list under the medical benefit is being modified to include only those that are considered medical benefit drugs. Access our Clinical Criteria to view the complete information for these step therapy updates. Clinical Criteria | Status | Drug | HCPCS or CPT code(s) | CC-0002 | Non-preferred | Nypozi | C9399, J3590 | CC-0003 | Non-preferred | Yimmugo | J3590 |
Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity. Site of care updatesEffective for dates of service on and after February 1, 2025, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our site of care review process. Access our Clinical Criteria to view the complete information for these site of care updates. Clinical Criteria | Drug | HCPCS or CPT code(s) | CC-0003 | Alyglo (immune globulin intravenous, human-stwk) | J1599 | CC-0066 | Tyenne (tocilizumab-aazg) | Q5135 |
Quantity limit updatesEffective for dates of service on or after February 1, 2025, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our quantity limit review process. Access our Clinical Criteria to view the complete information for these quantity limit updates. Clinical Criteria | Drug | HCPCS or CPT code(s) | CC-0266 | Rytelo (imetelstat) | C9399, J9999 | CC-0027 | Jubbonti; Wyost (denosumab-bbdz) | Q5136 |
Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CM-069728-24-CPN69536 Pre-service clinical review of non-oncology specialty pharmacy drugs will be managed by the Medical Specialty Drug Review team for Anthem. Oncology drugs will be managed by Carelon Medical Benefits Management, Inc., a separate company. Visit the Clinical Criteria in pharmacy website to access Clinical Criteria information. Coding updates effective February 15, 2025 Due to updates in the coding for the claims system, the claim system edits for the following Clinical Criteria will be revised. This will result in the review of claims for certain diagnoses before processing occurs to determine whether the service meets medical necessity criteria. As a result, these coding updates may result in a not medically necessary determination: - CC-0062 Tumor Necrosis Factor Antagonists
- CC-0214 Carvykti (ciltacabtagene autoleucel)
- CC-0259 Amtagvi (lifleucel)
Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CM-069959-24 Enhanced adherence mitigates healthcare costs and improves patient outcomes and quality of life. Promoting medication adherence and advocating for statin use among diabetes patients is critical. Statin use in diabetes:- Diabetics are two to four times more likely to die from heart disease (American Heart Association).
- Statins lower LDL cholesterol, reducing cardiovascular events by 25 to 60%.
- Statin use is low, particularly in younger, female, and black individuals.
- Delayed statin use increases cardiovascular disease risk in diabetic patients.
- National guidelines recommend statin therapy for diabetics ages 40 to 75, regardless of LDL levels.
- CMS has adopted the Statin Use in Persons with Diabetes (SUPD) measure to combat cardiovascular death in diabetic patients.
Medication adherence:- Poor adherence increases morbidity and mortality, causing more than 125,000 deaths and 10% of hospitalizations annually in the United States.
- Forty-five percent of U.S. adults have hypertension and only 24% manage it effectively, largely due to non-adherence.
- High adherence in diabetic patients reduces hospitalization risks by 30%.
- Improved adherence can save $1,200 to $8,000 per patient annually.
Supporting patients:- Simplify the regimen: Prescribe medications with fewer daily doses.
- Regular follow-ups: Ensure correct medication use and adjust doses as needed.
- Clear communication: Explain medication benefits, risks of non-compliance, and side effects.
- Extended prescriptions: Provide 90 to 100 days’ supply and sufficient refills.
- Home delivery: Eliminate transportation barriers.
- Address statin hesitancy: Discuss pros and cons and involve family in decisions.
- Use technology: Set up reminders through mobile apps, SMS, email, or pill containers.
- Address cost issues: Prescribe affordable options and explore assistance programs.
- Personalized care: Tailor medication plans to the patient's lifestyle and needs.
References: - American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2024. Diabetes Care 2024;47(Suppl. 1):S179–S218
- Bradley CK, Wang TY, Li S, et al. Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. Journal of the American Heart Association. 2019;8(7). doi: https://doi.org/10.1161/jaha.118.011765
- Wall HK, Ritchey MD, Gillespie C, Omura JD, Jamal A, George MG. Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 — United States, 2011–2016. MMWR Morb Mortal Wkly Rep 2018;67:983–991. doi: http://dx.doi.org/10.15585/mmwr.mm6735a4
- 2 Tarn DM, Barrientos M, Pletcher MJ, et al. Perceptions of Patients with Primary Nonadherence to Statin Medications. The Journal of the American Board of Family Medicine. 2021;34(1):123-131. doi: https://doi.org/10.3122/jabfm.2021.01.200262
- CDC. Statins and Diabetes: What You Should Know. Centers for Disease Control and Prevention. Published January 30, 2023. https://www.cdc.gov/diabetes/library/features/Statins_Diabetes.html
- Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117–125
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11). doi: https://doi.org/10.1161/cir.0000000000000678
- Collins R, Reith C, Emberson J, et al. The Lancet. 2016;388(10059):2532-2561Interpretation of the evidence for the efficacy and safety of statin therapy. doi: https://doi.org/10.1016/S0140-6736(16)31357-5
- Hla D, Jones R, Blumenthal RS, et al. Assessing severity of statin side effects: Fact vs fiction. American College of Cardiology. April 09, 2018. Accessed May 17, 2023. https://www.acc.org/latest-in-cardiology/articles/2018/04/09/13/25/assessing-severity-of-statin-side-effects
- Reston JT, Buelt A, Donahue MP, Neubauer B, Vagichev E, McShea K. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease. Annals of Internal Medicine. 2020;173(10):806-812. doi: https://doi.org/10.7326/m20-4680
- Brown M, Sinsky CA. Medication Adherence. Improve Patient Outcomes and Reduce Costs. American Medical Association Steps Forward. 5 June 2015. https://edhub.ama-assn.org/steps-forward/module/2702595. Accessed 16 May 2023
- Eight reasons patients don’t take their medications. American Medication Association. Feb 22, 2023. Accessed May 17, 2023. https://www.ama-assn.org/delivering-care/patient-support-advocacy/8-reasons-patients-dont-take-their-medications
- El Halabi J, Minteer W, Boehmer KR. Identifying and Managing Treatment Nonadherence. Medical Clinics of North America. 2022;106(4):615-626. doi: https://doi.org/10.1016/j.mcna.2022.02.003
Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. MULTI-BCBS-CR-069868-24-CPN69806 At a glance: - Care providers must prepare for HEDIS® medical record reviews starting January 2025.
- Care providers will submit records through Remote Electronic Medical Record (EMR) Access Service, website upload, fax, secure file transfer protocol (SFTP), mail, or on-site.
BackgroundEach year, we perform a review of a sample of our members’ medical records as part of the HEDIS quality study. HEDIS is part of a nationally recognized quality improvement initiative and is used by the Centers for Medicare & Medicaid Services (CMS), the National Committee for Quality Assurance (NCQA), and several states to monitor the performance of managed care organizations. We will begin requesting medical records in January 2025. No special authorization is needed for you to share member medical record information with us since quality assessment and improvement activities are routine parts of healthcare operations. Ways to submit your records in our preferred order:- Remote EMR Access Service: We offer the Remote EMR Access Service to care providers to submit member medical record information to us. If you are interested in more information, contact us at Centralized_EMR_Team@anthem.com.
- Upload: Medical records can be uploaded to our secure website using the instructions in the request document.
- Fax: Medical records can be faxed to us using the instructions in the request document.
- SFTP: Medical records can be uploaded via a secure website.
- U. S. Postal Service: Medical records can be mailed to us using the instructions in the request document.
- On-site: Medical records can be pulled by a representative at your local office where medical records are located.
HEDIS review is time sensitive, so submit the requested medical records within the timeframe indicated in the initial HEDIS request document. We appreciate the care you provide our members. Your assistance is crucial to ensuring our data is statistically valid, auditable, and accurately reflects quality performance. Contact usAvaility Chat with Payer is available during normal business hours. Get answers to your questions about eligibility, benefits, authorizations, claims status, and more. To access Availity Essentials, go to https://Availity.com and select the appropriate payer space tile from the drop-down. Then, select Chat with Payer and complete the pre-chat form to start your chat. For additional support, visit the Contact Us section of our provider website for the appropriate contact. HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA). Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Medicare services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC., or Anthem Blue Cross and Blue Shield Retiree Solutions, trade name of Anthem Insurance Companies, Inc. Commercial services provided by Anthem Blue Cross and Blue Shield, trade name of Anthem HealthChoice HMO, Inc. and Anthem HealthChoice Assurance, Inc., or Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CDCRCM-069946-24-CPN69632, NYBCBS-CDCRCM-071179-24-CPN71157 The Consumer Assessment of Healthcare Providers and Systems® (CAHPS) is an annual standardized survey conducted anonymously by a third-party vendor (Center for the Study of Services) to assess a random sample of consumers' experiences with their health plan, their personal provider, and healthcare services. Refer to attachment to view full details. CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ). Medicaid services provided by Anthem Blue Cross and Blue Shield HP, trade name of Anthem HP, LLC. Independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc. NYBCBS-CD-068377-24-CPN67980 ATTACHMENTS (available on web): Provider: CAHPS awareness (pdf - 0.08mb) |